Skip to main content

This job has expired

International Medical Director, Hematology

Employer
F.Hoffmann-La Roche
Location
Basel, Canton of Basel-Stadt (CH)
Salary
not shown
Closing date
Apr 18, 2019

Job Details

International Medical Director, Hematology

The International  Medical Director (IMD), reporting to the Group International Medical Director (GIMD) for the Myeloid-Benign Global Medical Team, is a core role to support the joint planning and execution of the Medical and Evidence Generation Strategy for the assigned product(s) / Indication(s) based on key insights and perspectives from multiple stakeholders.

 

The role requires an outstanding track record of previous experience in Medical Affairs, preferably with Hematology-Hemophilia expertise.

 

Main responsibilities:

Medical Strategy

  • Accountable for the evidence generation strategy planning and execution, incl. (but not limited to) identifying medical and access gaps and needs as part of the overall medical strategy
  • Responsible for the joint planning and execution of the Medical Strategy for the assigned product(s) / Indication(s)

Evidence Generation Strategy Planning and Execution

  • Drives and leads the strategy of the integrated evidence generation activities, incl. Roche sponsored clinical studies, Investigator Initiated Studies (IIS), RWD
  • Accountable for evidence generation activities for the assigned product (s) / Indication(s), including risk benefit assessment and medical monitoring in all medical affairs interventional studies
  • Takes the role of Lead Scientific Responsible and acts as a member of the Study Management Team (SMT)  
  • Assesses the needs and coordinates compassionate use of the assigned product(s)

Patient Access

  • In collaboration with Global Access (GA) and appropriate Affiliates stakeholders, identifies the evidence generation needs/gaps in order to obtain and maintain patient access and integrates them into the evidence generation strategy
  • Provides medical expertise and input into the market access, brand and lifecycle strategies and plans (e.g. Life Cycle Plans, Brand Plans, Launch Plans,  Comparative Benefit Risk Assessments and other relevant documents)

External Collaborations

  • Develops, advances and maintains TAE interactions and collaborations, incl. those aimed to set up and conduct evidence generation activities
  • Represents Roche in peer-to-peer interactions with external collaboration partners, including in patient-company interactions

 

We are looking for a MD with relevant clinical experience (patient care decision-making) at the point of care. Specialization degree and experience in the disease area are a plus. With relevant pharmaceutical industry experience in Medical Affairs function (preferably at Global or Regional level)​. You will bring:

  • Experience in Evidence Generation within or outside the pharmaceutical industry, including protocol-writing.
  • Experience in Compassionate Use Program/Compassionate Use Request management
  • Understanding of business context, access and regulatory environments and trends
  • Experienced educator/ presenter.
  • Experience of partnership with therapeutic area experts and external organizations is strongly preferred
  • Previous experience with launch of drugs/indications is preferred
  • Clinical or scientific experience in the field of Hematology-Hemophilia is a plus.
  • Fluency in written and spoken English

Functional competencies, including but not limited to, organization, prioritization and planning skills, negotiation skills, communication & presentation skills

 

Roche is an equal opportunity employer.

Company

About Roche


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert